iiinova — where your digital self keeps evolving

Beth Faiman

@bethfaiman.bsky.social

Beth Faiman @bethfaiman.bsky.social · 24/09/2024

Fortunate to speak to colleagues in Brasil / Portuguese about #MM and #CART, #bispecifics. What a unique honor @mmkingt.bsky.social

010

Reposted by Beth Faiman

Orla McCourt @orlamccourt.bsky.social · 24/09/2024

There's very little published on #rehabilitation in #CAR-T. A short report sharing insights from our service pilot of #physiotherapy input before and after CAR-T @UCLH has been published in eJHaem onlinelibrary.wiley.com/doi/10.1002/...

onlinelibrary.wiley.com

Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy

Introduction This report outlines the evaluation of physiotherapist-led prehabilitation/rehabilitation for recipients of chimeric antigen receptor T (CAR-T) cell therapy. Methods A hybrid approach...

032

Beth Faiman @bethfaiman.bsky.social · 20/09/2024

So happy to have you in Houston at the #IMF #myeloma meeting to kick off!

011

Reposted by Beth Faiman

Tracy King @mmkingt.bsky.social · 15/09/2024

Nurse/AH welcome all to join us @myeloma-society.bsky.social travel safe - c u in Rio! events.jspargo.com/ims24/CUSTOM...

065

Reposted by Beth Faiman

Myeloma Society @myeloma-society.bsky.social · 16/09/2024

Don't miss this Meet the Expert session on Saturday, September 28 at #IMS24. Register now!➡️ rb.gy/1h136x

011

Beth Faiman @bethfaiman.bsky.social · 11/09/2024

T-14 days until #IMS24! @rahulbanerjeemd.bsky.social

011

Reposted by Beth Faiman

Rahul Banerjee, MD, FACP @rahulbanerjeemd.bsky.social · 08/09/2024

1/ And since we can’t tweet during #IMS24, also worth highlighting CEPHEUS as another LBA! D-VRd vs VRd in ASCT-ineligible #MMsm - large PFS benefit with CD38 addition even if no ASCT. Love simplicity of the last line: ASCT decision-making should not dictate induction choice!

151

Beth Faiman @bethfaiman.bsky.social · 10/09/2024

Where are my #myeloma peeps?

060